Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all oncology indications in Europe and specified markets.

GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, Brazil, India and South Korea. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Financial terms of the partnership include an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. In Europe, Amgen and GlaxoSmithKline will share profits after accounting for expenses associated with the partnership. In emerging markets, GlaxoSmithKline will be responsible for all commercialization expenses and purchase denosumab from Amgen to meet demand.

The companies' combined commercialization activities will expand access to denosumab, once approved, to patients worldwide who are afflicted by osteoporosis and other bone loss conditions.

"Our collaboration with GlaxoSmithKline will help Amgen bring the promise of denosumab to patients in Europe and other parts of the world more effectively than if we commercialized the drug globally on our own," said Amgen CEO Kevin Sharer. "Amgen and GlaxoSmithKline
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
...  Cenestra Health announces that the U.S. Patent and Trademark ... No. 8,071,646 (the ",646 patent"), that protects and provides ... acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging ... provides exclusivity for these EPA:DHA ratios in compositions with ...
... of up to 25 percent in two barely separated ... Designers of next-generation devices using nanowires to deliver electric ... solar arrays may need to make allowances for ... for 20 years," says Sandia lead researcher Mike Lilly. ...
... RATON, Fla., Dec. 7, 2011 /PRNewswire-iReach/ -- ... Herb Pharma, Switzerland: the best and most powerful weapons ... Although aging is a natural process, no-one ... neck and decolletage, which are on display most of ...
Cached Biology Technology:Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 2Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 3Voltage increases up to 25 percent observed in closely packed nanowires at Sandia Labs 2Voltage increases up to 25 percent observed in closely packed nanowires at Sandia Labs 3Fytofontana Cosmeceuticals: The Swiss Secret For Incredibly Young And Beautiful Skin 2
(Date:4/17/2014)... Sodium channels are implicated in many serious conditions such ... important potential target for drug therapies. Unfortunately, there is ... New Cambridge research provides fresh and unexpected insight into ... its components - β-subunit molecules - which are responsible ... is published in the most recent edition of the ...
(Date:4/17/2014)... genetic information of DNA is used to manufacture ... different functions in living organisms. Messenger RNA (mRNA) ... by relating the genetic information of DNA to ... , By examining the different types and amounts ... a given time, researchers can determine which specific ...
(Date:4/17/2014)... International researchers, led by the Australian National University ... sea-level changes and deep-sea temperature variability over the ... scientists better understand the climate surrounding ice ages ... help determine the relationship between carbon dioxide levels, ... ANU, the University of Southampton (UoS) and the ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2
... has long been used topically in many skin creams ... for the skin. Now, new research just published in ... consuming flavanol-rich cocoa and how it might actually benefit ... certain components in cocoa may actually help improve the ...
... vaccines may increase elderly patients' immune response without ... protection against the flu, according to an article ... Internal Medicine, one of the JAMA/Archives journals. , ... for 50 years to prevent flu and its ...
... the Stanford University School of Medicine have taken a ... that could eventually be transplanted into living organisms. , ... resident Oscar Abilez, MD, and colleagues have successfully differentiated ... blocks of blood vessels, after placing them in a ...
Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2High-dose flu vaccines appear to safely boost immunity in elderly 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3
... for Membrane Proteins ,Contains sufficient components ... for 2-D gel analysis , ,Includes:, ... , (contains sufficient reagents for ... cell weight of 10 mg each) Kit ...
... The Amplifluor UniPrimer-fluorescein is a hairpin ... transfer pair (fluorescein and non-fluorescent quencher) ... The UniPrimer is identical to ... Universal Detection System (S7901) and is ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
Biology Products: